Journals / Türk Kardiyoloji Derneği Arşivi / 2018 / Cilt: 46 - Sayı: 1

Simultaneous total occlusion of two coronary arteries associated with use of drospirenone-ethinyl estradiol (oral contraceptive)

Drospirenon-etinil estradiol (oral kontraseptif) kullanımına bağlı iki koroner arterin eş zamanlı tam tıkanması

Pages
69–72
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

To the best of our knowledge, thisis the first case report of simultaneous total occlusion of 2coronary arteries associated with the use of drospirenoneethinyl estradiol in the English-language medical literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Although the use of oral contraceptives is associated with an increased risk of venous thromboembolicdisease, the risk of myocardial infarction (MI) is unclear.
📊
Key Findings & Data:In this report, a 33-year-oldwoman who had used drospirenone-ethinyl estradiol for 6months was admitted with MI and symptoms of cardiogenicshock.
💡
Conclusion & Impact:To the best of our knowledge, thisis the first case report of simultaneous total occlusion of 2coronary arteries associated with the use of drospirenoneethinyl estradiol in the English-language medical literature.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Although the use of oral contraceptives is associated with an increased risk of venous thromboembolicdisease, the risk of myocardial infarction (MI) is unclear. Anew, third-generation contraceptive agent, drospirenoneethinyl estradiol, which contains less estrogen and a newprogestogen, drospirenone, in a different combination, hasbeen considered more reliable in terms of risk of MI. However, there have been some cases of MI associated with theuse of drospirenone-ethinyl estradiol, despite the protectiveeffects of this oral contraceptive. In this report, a 33-year-oldwoman who had used drospirenone-ethinyl estradiol for 6months was admitted with MI and symptoms of cardiogenicshock. Coronary angiography revealed the total occlusionof 2 coronary arteries and so percutaneous coronary intervention was performed. To the best of our knowledge, thisis the first case report of simultaneous total occlusion of 2coronary arteries associated with the use of drospirenoneethinyl estradiol in the English-language medical literature.

Özet

Oral kontraseptiflerin kullanımına bağlı olarak venöz tromboemboli riski artmasına rağmen, miyokart enfarktüsü (ME) riski tam belli değildir. Yeni bir üçüncü kuşak oral kontraseptif ajan olan drospirenon-etinil estradiol daha düşük östrojen ve yeni bir progesteron olan drosperidonun farklı kombinasyonundan oluşmakta olup, ME riski açısından daha güvenilir kabul edilmektedir. Bununla birlikte drospirenon-etinil estradiol kullanımına bağlı ME olguları bildirilmiştir. Bu yazıda, altı aydır drospirenon-etinil estradiol kullanan ve ME ve kardiyojenik şok belirtileri ile başvuran 33 yaşında bir kadın hasta sunuldu. Koroner anjiyografide iki koroner arterin aynı anda tam tıkandığı görülüp, hastaya primer perkütan koroner girişim yapıldı. Bildiğimiz kadarıyla, bu olgu İngilizce tıp literatürü tarandığında drospirenon-etinil estradiol’ün kullanımıyla ilişkili iki koroner arterin eşzamanlı olarak tam tıkanmasıyla sonuçlanan ilk olgudur.

🔖

Cite This Article

Kiriş, T., Köprülü, D., Şahin, İ., Zeren, G., Atmaca, H. (2022). Simultaneous total occlusion of two coronary arteries associated with use of drospirenone-ethinyl estradiol (oral contraceptive). Türk Kardiyoloji Derneği Arşivi, Cilt: 46 - Sayı: 1, 69–72. https://ajindex.com/articles/632137

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Spitzer WO, Faith JM, MacRae KD. Myocardial infarction and third generation oral contraceptives: aggregation of recent studies. Hum Reprod 2002;17:2307–14. [CrossRef] 2. Margolis KL, Adami HO, Luo J, Ye W, Weiderpass E. A prospective study of oral contraceptive use and risk of myocardial infarction among Swedish women. Fertil Steril 2007;88:310–6. [CrossRef] 3. Keeling D. Combined oral contraceptives and the risk of myocardial infarction. Ann Med 2003;35:413–8. [CrossRef] 4. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29–38. [CrossRef] 5. Kocabay G, Yildiz M, Ozkan M. Acute myocardial infarction due to oral contraceptive. Clin Appl Thromb Hemost 2009;15:364–5. [CrossRef] 6. Ortí G, Mira Y, Vaya A. Acute myocardial infarction associated with Yasmin oral contraceptive. Clin Appl Thromb Hemost 2007;13:336–7. [CrossRef] 7. Ouyang P, Michos ED, Karas RH. Hormone replacement therapy and the cardiovascular system lessons learned and unanswered questions. J Am Coll Cardiol 2006;47:1741–53. 8. Lacut K, Oger E, Le Gal G, Blouch MT, Abgrall JF, Kerlan V, et al. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. Thromb Haemost 2003;90:124–31. 9. Girolami A, Tezza F, Allemand E, Girolami B. Arterial thrombosis and drospirenone-containing pill (Yasmin). Is the pill to be absolutely avoided by women who smoke? J Thromb Thrombolysis 2008;26:163–4. [CrossRef] 10. Miller GJ, Bauer KA, Cooper JA, Rosenberg RD. Activation of the coagulant pathway in cigarette smokers. Thromb Haemost 1998;79:549–53. 11. Tanis BC, van den Bosch MA, Kemmeren JM, Cats VM, Helmerhorst FM, Algra A, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001;345:1787– 93. [CrossRef] 12. Karabay CY, Kocabay G, Oduncu V, Kalayci A, Guler A, Karagöz A, et al. Drospirenone-containing oral contraceptives and risk of adverse outcomes after myocardial infarction. Catheter Cardiovasc Interv 2013;82:387–93. [CrossRef] 13. Vlaar PJ, Svilaas T, van der Horst IC, Diercks GF, Fokkema ML, de Smet BJ, et al. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet 2008;371:1915– 20. [CrossRef]